Grading neuroendocrine cancer

Last medical review:

Grading describes how the cancer cells look compared to normal, healthy cells. Knowing the grade gives your healthcare team an idea of how quickly the cancer may be growing and how likely it is to spread. This helps them plan your treatment. The grade can also help the healthcare team predict future outcomes (prognosis) and how the cancer might respond to treatment.

The grade helps classify neuroendocrine cancer into neuroendocrine tumour (NET) and neuroendocrine carcinoma (NEC). When talking about the grade, doctors may describe neuroendocrine cancer as a neuroendocrine neoplasm (NEN).

To find out the grade of neuroendocrine cancer, a pathologist looks at a tissue sample from the tumour under a microscope. They look at how different the cells are from normal cells (called differentiation), such as the size and shape of the cells and how the cells are arranged. They can usually tell how fast a tumour is growing by looking at how many cells are dividing.

The following factors help grade neuroendocrine cancer:

  • how often the cells of the tumour are dividing (measured as mitotic count)
  • the amount of Ki-67 (a specific protein) made during division (measured as a percentage)
  • the number of dead cells or tissues that are in the tissue sample (called necrosis)

Neuroendocrine tumours (NETs)

A neuroendocrine tumour (NET) is well differentiated. This means the cancer cells are abnormal but look a lot like normal cells and are arranged a lot like normal cells. The pathologist gives a NET a grade from 1 to 3. A lower number means the tumour is a lower grade. NETs with a higher mitotic count and a higher Ki-67 percentage are given a higher grade. But the exact cut-off values between the grades may differ depending on where the NET started in the body.

Low-grade (grade 1, or G1) NETs have cancer cells that tend to grow slowly and are less likely to spread.

Intermediate-grade (grade 2, or G2) NETs have cancer cells that tend to grow and divide more quickly than normal cells.

High-grade (grade 3, or G3) NETs have cancer cells that tend to grow quickly and are more likely to spread than G1 or G2 NETs. The cells also look more abnormal compared with G1 or G2 NETs.

Neuroendocrine carcinomas (NECs)

A neuroendocrine carcinoma (NEC) is poorly differentiated. This means the cancer cells don’t look like normal cells and are arranged very differently. NECs with small and round cells are called small cell neuroendocrine carcinomas. NECs with large cells are called large cell neuroendocrine carcinomas.

NECs are always high grade (grade 3, or G3). They tend to grow more quickly and spread faster than G3 NETs.

Expert review and references

  • Sylvia Asa, MD, PhD
  • Canadian Neuroendocrine Tumour Society (CNETS). Neuroendocrine Tumours: Reference Guide for Patients and Families (Version 3). 2020. https://cnets.ca/.
  • Macmillan Cancer Support. Staging and Grading of Neuroendocrine Tumours (NETs). 2022. https://www.macmillan.org.uk/.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors Version 2.2024. 2024.
  • Neuroendocrine Cancer UK. Neuroendocrine Cancer Virtual Patient Handbook. 2023. https://www.neuroendocrinecancer.org.uk/.
  • Pavel M, Öberg k, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020: 31(7):844–860.
  • Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine Pathology. 2022: 33(1):115–154.
  • Sultana Q, Kar J, Verma A, et al. A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management. Journal of Clinical Medicine. 2023: 12(15):5138.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society